Q&A: PureTech CEO Daphne Zohar talks biotech interests on Capitol Hill
As the year is nearing a close, lawmakers are still chipping away at spending bills and a long to-do list of health policy priorities that could come with some big changes for the biotech industry.
Endpoints News sat down with PureTech CEO and BIO board member Daphne Zohar to talk about the biggest issues facing biotech, what she urged lawmakers to prioritize during recent meetings on Capitol Hill with BIO board members, and why she thinks biotech needs to be legislated differently than pharma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.